• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Thursday, October 31, 2019

    Offline Date

    Thursday, April 30, 2020

    ACPE Expiration Date

    Monday, October 31, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      This session will discuss the emerging roles of immunotherapy and targeted therapy in the management of non-small cell lung cancer. Immunotherapy, either alone or in combination with chemotherapy, has become the new standard of care for most patients with non-small cell lung cancer without a targetable mutation. We will review the trials that have led to this change in practice. 

      Handouts

      • Slide Document :   ce_2_slides.pdf

      Financial Support By

      joint funding from Advanced Accelerator Applications, a Novartis Company, BMS and Pfizer Alliance, Celgene Corporation, Merck & Co., Inc., and Pfizer
    • Pharmacist

      Apply best practices to manage the adverse events associated with the new therapies available for advanced non-small cell lung cancer.
      Identify clinical evidence for new and emerging treatment options in advanced non-small cell lung cancer.
      Describe key patient counseling and monitoring considerations for immunotherapy and targeted therapies in non-small cell lung cancer.

      Nurse

      Describe key patient counseling and monitoring considerations for immunotherapy and targeted therapies in non-small cell lung cancer.
      Apply best practices to manage the adverse events associated with the new therapies available for advanced non-small cell lung cancer.
      Identify clinical evidence for new and emerging treatment options in advanced non-small cell lung cancer.
    • Activity Type

      Application

      CE Broker

      20-747190

      Universal Activity Number

      Pharmacist 0798-0000-19-193-H01-P
      Nurse 0798-0000-19-193-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Sally  Barbour, PharmD, BCOP, CPP, FHOPA
      Director, Oncology Pharmacy Programs, Oncology Pharmacy Residency Program Director; Duke University Medical Center Clinical Pharmacist Practitioner

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).